Abeona Therapeutics receives Orphan Drug Designation in EU for ABO-101 gene therapy
Abeona Therapeutics announced the EMA Committee for Orphan Medicinal Products has granted Orphan Drug Designation for Abeona’s gene therapy program ABO-101 for children impacted by Sanfilippo syndrome type B, a rare autosomal recessive disease that causes neurocognitive decline in children. January 19, 2017